江苏四环生物股份有限公司 2019 年年度报告全文 江苏四环生物股份有限公司 2019 年年度报告 2020 年 04 月 1 江苏四环生物股份有限公司 2019 年年度报告全文 第一节重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连 带的法律责任。 公司负责人孙国建、主管会计工作负责人及会计机构负责人(会计主管人员) 徐海珍声明：保证年度报告中财务报告的真实、准确、完整。 释义 | 释义项 | 指 | 释义内容 | | --- | --- | --- | | 公司、本公司 | 指 | 江苏四环生物股份有限公司 | | 北京四环 | 指 | 北京四环生物制药有限公司 | | EPO | 指 | 重组人促红素注射液 | | G-CSF | 指 | 重组人粒细胞刺激因子注射液 | | 晨薇、晨薇生态园 | 指 | 江苏晨薇生态园科技有限公司 | | 广西洲际林业 | 指 | 广西洲际林业投资有限公司 | 4 江苏四环生物股份有限公司 2019 年年度报告全文 所有董事均已出席了审议本报告的董事会会议。 本年 ...

江苏四环生物股份有限公司 2019 年第三季度报告全文 江苏四环生物股份有限公司 2019 年第三季度报告 2019 年 10 月 1 江苏四环生物股份有限公司 2019 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 董事许琦表示公司因涉嫌信息披露违规被中国证监会立案调查，其对现任 的财务还是缺乏足够的信任度，因此其无法保证本报告内容的真实、准确、完 整，请投资者特别关注。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人孙国建、主管会计工作负责人及会计机构负责人(会计主管人员) 徐海珍声明：保证季度报告中财务报表的真实、准确、完整。 2 江苏四环生物股份有限公司 2019 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 8 ...

江苏四环生物股份有限公司 2019 年半年度报告全文 第一节 重要提示、目录和释义 江苏四环生物股份有限公司 2019 年半年度报告全文 江苏四环生物股份有限公司 2019 年半年度报告 2019 年 08 月 1 所有董事均已出席了审议本报告的董事会会议。 本年度报告涉及的未来计划、发展战略等前瞻性描述不构成公司对投资者 的实质承诺，敬请投资者注意风险。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | ﮯ | | --- | | 2019 | 年半年度报告 1 | | --- | --- | | 第一节 | 重要提示、释义 2 | | 第二节 | 公司简介和主要财务指标 5 | | 第三节 | 公司业务概要 8 | | 第四节 | 经营情况讨论与分析 10 | | 第五节 | 重要事项 16 | | 第六节 | 股份变动及股东情况 21 | | 第七节 | 优先股相关情况 24 | | 第八节 | 董事、监事、高级管理人员情况 25 | | 第九节 | 公司债相关情况 26 | | 第十节 | 财务报告 27 | | 第十一节 | 备查文件目录 112 | 公司董事会、监事会及董事、监事、高 ...

江苏四环生物股份有限公司 2019 年第一季度报告全文 江苏四环生物股份有限公司 2019 年第一季度报告 2019 年 04 月 1 江苏四环生物股份有限公司 2019 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人孙国建、主管会计工作负责人及会计机构负责人(会计主管人员) 徐海珍声明：保证季度报告中财务报表的真实、准确、完整。 2 江苏四环生物股份有限公司 2019 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 67,767,425.29 | 86,036,603.08 | -21.23% | | 归属于上市公司股东的净利润（元） | -12,792,592.57 | 3,565,354. ...

江苏四环生物股份有限公司 2018 年年度报告全文 江苏四环生物股份有限公司 2018 年年度报告 2019 年 04 月 1 江苏四环生物股份有限公司 2018 年年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连 带的法律责任。 公司负责人孙国建、主管会计工作负责人及会计机构负责人(会计主管人员) 徐海珍声明：保证年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 中审众环会计师事务所（特殊普通合伙）为公司出具了带强调事项段的无 保留意见的审计报告，本公司董事会、监事会对相关事项已有详细说明，请投 资者注意阅读。 本年度报告涉及的未来计划、发展战略等前瞻性描述不构成公司对投资者 的实质承诺，敬请投资者注意风险。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | \l | - _Toc300000084 | 第一节 重要提示、目录和释义 | 5 | | --- | --- | --- | --- | | 第二节 | | 公司简介和主要财 ...

江苏四环生物股份有限公司 2018 年第三季度报告正文 证券代码：000518 证券简称：四环生物 公告编号：临-2018-38 号 江苏四环生物股份有限公司 2018 年第三季度报告正文 1 江苏四环生物股份有限公司 2018 年第三季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人孙国建、主管会计工作负责人及会计机构负责人(会计主管人员) 徐海珍声明：保证季度报告中财务报表的真实、准确、完整。 2 江苏四环生物股份有限公司 2018 年第三季度报告正文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 904,069,868.18 | | 931,628,406.78 | -2.96% | | 归属于上市 ...

Financial Performance - The company's operating revenue for the first half of 2018 was CNY 180,903,654.71, a decrease of 8.31% compared to CNY 197,309,155.11 in the same period last year[18]. - The net profit attributable to shareholders of the listed company was CNY 1,028,739.53, down 94.61% from CNY 19,092,935.66 in the previous year[18]. - The net profit after deducting non-recurring gains and losses was CNY 543,126.75, an increase of 110.37% compared to a loss of CNY 5,238,437.45 in the same period last year[18]. - The net cash flow from operating activities was CNY 19,029,873.53, a significant improvement of 106.46% compared to a negative cash flow of CNY 294,637,435.45 in the previous year[18]. - The weighted average return on net assets was 0.16%, down from 3.29% in the previous year, indicating a decline in profitability[18]. - The company reported a net loss of CNY 474,196,966.43, compared to a loss of CNY 475,225,705.96 at the beginning of the period, indicating a slight improvement[95]. - The company reported a total cash outflow from investing activities of 13,037.59 CNY, resulting in a net cash flow from investing activities of -13,037.59 CNY[114]. - The total comprehensive income for the period was CNY 18,161.12 million, down from CNY 80,321.42 million, reflecting a decline of about 77.6%[107]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 924,582,760.89, a decrease of 0.76% from CNY 931,628,406.78 at the end of the previous year[18]. - The total liabilities decreased to CNY 249,390,291.98 from CNY 256,083,448.72, a reduction of approximately 2.9%[94]. - Current assets totaled CNY 761,637,480.06, down from CNY 769,785,095.16 at the beginning of the period, indicating a decrease of approximately 3.5%[93]. - Cash and cash equivalents increased to CNY 47,300,795.13 from CNY 40,728,343.14, reflecting an increase of about 16%[92]. - Total liabilities rose slightly to CNY 131,114,228.20 compared to CNY 129,325,360.05 in the previous period[99]. - The total equity attributable to shareholders was CNY 606,003,232.93, up from CNY 587,842,107.99[99]. Business Strategy and Development - The company plans to transform its business towards the ecological agriculture and forestry industry, having established Jiangsu Chenwei Ecological Park Technology Co., Ltd. in 2015 and acquired Guangxi Intercontinental Forestry Investment Co., Ltd. in 2017[24]. - The company is focusing on optimizing its profitability and enhancing its sustainable development capabilities amid a challenging pharmaceutical industry environment[24]. - The company is actively expanding its ecological landscape projects in Jiangyin and Yunnan, contributing to its growth strategy[32]. - The company has plans for market expansion, focusing on new product development and technological advancements[121]. - The company is exploring potential mergers and acquisitions to strengthen its market position and expand its operational capabilities[121]. Research and Development - Research and development expenses increased by 38.46% to CNY 4,876,783.95, reflecting the addition of new R&D projects[34]. - The company aims to enhance its research and development efforts to drive innovation in its product offerings[121]. Shareholder Information - The company does not plan to distribute cash dividends or issue bonus shares for the reporting period[6]. - The total number of ordinary shareholders at the end of the reporting period was 71,034[77]. - The largest shareholder, Wang Hongming, holds 14.00% of the shares, totaling 144,138,394 shares[78]. - The company did not experience any changes in its controlling shareholder or actual controller during the reporting period[79]. Risks and Challenges - The company faces risks from government policies on drug pricing and procurement, which may negatively impact performance[45]. - The company has not engaged in any significant asset or equity transactions during the reporting period[42]. Compliance and Accounting - The company adheres to the accounting standards set by the Ministry of Finance, ensuring the financial statements reflect its financial status accurately[134]. - The company’s accounting period runs from January 1 to December 31 each year[135]. - The company’s business cycle is 12 months[136]. - The reporting currency for the company is Renminbi[137]. Inventory and Asset Management - The company uses a perpetual inventory system for inventory management[167]. - Inventory is valued using the weighted average method upon issuance[165]. - The net realizable value of inventory is determined based on estimated selling prices minus estimated costs and related taxes[166]. Financial Instruments and Investments - Financial instruments include financial assets, financial liabilities, and equity instruments, classified at initial recognition based on their measurement and recognition criteria[151]. - The company recognizes financial assets at fair value, deducting any declared but unpaid cash dividends or interest, with changes in fair value recognized in current profit or loss[153].

Financial Performance - The company's operating revenue for 2017 was CNY 346,054,646.61, representing a 5.73% increase compared to CNY 327,313,301.33 in 2016[18]. - The net profit attributable to shareholders for 2017 was CNY 7,288,394.73, a significant increase of 62.94% from CNY 4,472,925.91 in 2016[18]. - The basic earnings per share for 2017 was CNY 0.0071, up 65.12% from CNY 0.0043 in 2016[18]. - The company reported a significant decrease in net profit after deducting non-recurring gains and losses, which was negative CNY 14,881,852.83 in 2017, compared to positive CNY 571,115.46 in 2016, a decrease of 2,705.75%[18]. - The company reported a net profit attributable to ordinary shareholders of approximately 7.29 million in 2017, with a profit distribution plan of 0.00%[75]. - The company reported a net profit of 28,021,300.1 yuan from its subsidiary Beijing Sihuan Bio-Pharmaceutical Co., with total assets of 419,640,071 yuan[65]. - The company reported a total profit of CNY 75.69 million, a significant increase from CNY 1.59 million in the previous year, reflecting a growth of approximately 4,653%[184]. Cash Flow and Liquidity - The net cash flow from operating activities was negative CNY 10,785,813.91, a decline of 193.14% compared to CNY 11,579,773.72 in 2016[18]. - Operating cash inflow increased by 17.60% to ¥362,422,720.30, while operating cash outflow rose by 52.97% to ¥453,688,363.43[50]. - The company reported a net cash outflow from operating activities of CNY 10.79 million, contrasting with a net inflow of CNY 11.58 million in the previous year[188]. - The ending balance of cash and cash equivalents decreased to 2,269,199.59 yuan from 3,275,963.60 yuan, indicating a reduction in liquidity[193]. - The company experienced a net decrease in cash and cash equivalents of 1,006,764.01 yuan, contrasting with an increase of 3,270,091.46 yuan in the previous period, signaling cash management issues[193]. Assets and Liabilities - Total assets at the end of 2017 were CNY 931,628,406.78, down 8.43% from CNY 1,017,357,931.64 at the end of 2016[18]. - The total amount of accounts receivable was ¥112,408,616.90, which accounted for 12.07% of total assets[55]. - The total non-current assets decreased from CNY 341,458,948.04 to CNY 161,843,311.62, a decline of approximately 52.6%[171]. - Total liabilities decreased to CNY 129,325,360.05 from CNY 219,709,908.49, a reduction of 41.19%[178]. - The company has no long-term borrowings or bonds payable as of the end of the reporting period[173]. Inventory and Sales - The company reported a significant increase in inventory levels, with Interleukin inventory rising by 188.65% to 625,310 units[41]. - Total inventory rose to ¥584,108,713.27, up 17.33% from the previous year, largely due to the addition of inventory from Guangxi Intercontinental Forestry Investment Co., Ltd.[55]. - The sales volume of Interleukin decreased by 6.86% to 4,150,567 units, while production increased by 7.66% to 4,559,247 units[41]. - EPO sales volume increased by 14.17% to 4,552,480 units, with production rising by 18.60% to 4,632,410 units[41]. Strategic Initiatives and Market Focus - The company plans not to distribute cash dividends or issue bonus shares for the year[6]. - The company plans to consolidate its existing market in the pharmaceutical industry and aims to develop new products and expand into new markets[69]. - The company aims to improve its internal controls and management levels in 2018 to achieve its development goals[68]. - The company is recognized as a national high-tech enterprise with advanced technology and high product quality in the biopharmaceutical sector[31]. - The company’s strategic focus includes transitioning towards the ecological agriculture and forestry sector, leveraging the growing demand for urban landscaping[29]. Shareholder and Governance Structure - The total number of shares outstanding is 1,029,556,222, with 1,029,535,693 being unrestricted shares[109]. - The largest shareholder, Wang Hongming, holds 14.00% of the shares, totaling 144,138,394 shares, with 96,660,000 shares pledged[111]. - The company has no controlling shareholder or actual controller, indicating a dispersed shareholding structure[113][115]. - The board of directors consists of six members, including three independent directors, ensuring compliance with legal requirements[143]. - The company has established a comprehensive corporate governance structure to protect minority shareholders' rights[99]. Employee and Management Information - The total number of employees in the company is 280, with 272 in major subsidiaries and 8 in the parent company[134]. - The total remuneration for directors, supervisors, and senior management during the reporting period amounts to 114.74 million yuan[133]. - The average age of the current board members is approximately 46 years, indicating a relatively young leadership team[121]. - Xu Yin resigned as Chief Financial Officer on May 24, 2017, due to personal reasons[123]. - The company has seen a complete turnover in its board of directors and supervisors, with all positions being filled by new appointees[122]. Audit and Compliance - The audit opinion issued was a standard unqualified opinion, confirming the fair presentation of financial statements[160]. - The internal control audit report was disclosed on April 28, 2018, with no major defects found[156]. - The company has not been subject to any penalties from securities regulatory agencies in the past three years[129]. - Independent directors raised objections regarding the appointment of certain executives, reflecting their active role in governance[146].

Cost Structure - The cost structure of the main products shows that the raw material cost for Interleukin increased to 54.31% in 2017 from 51.01% in 2016, a rise of 3.30%[1] - EPO's raw material cost accounted for 73.46% of its total cost in 2017, up from 71.77% in 2016, reflecting a 1.69% increase[1] - G-CSF's raw material cost decreased to 59.27% in 2017 from 60.68% in 2016, a decline of 1.41%[1] - The total raw material cost for the pharmaceutical manufacturing sector was 39,908,472.21 yuan in 2017, representing 59.77% of the total operating cost, compared to 52,730,251.48 yuan and 49.41% in 2016, marking a 10.36% increase[2] Financial Performance - The company reported a net profit attributable to the parent company of 313.50 million yuan, with a decrease of 49.83% in 2017 compared to the previous year[4] Strategic Plans - The company plans to expand its market presence and enhance product offerings through strategic acquisitions and partnerships[4] - The company is focusing on the development of new technologies and products to drive future growth[4] - The company aims to maintain a competitive edge in the pharmaceutical industry through continuous innovation and market expansion strategies[4] Operational Improvements - The company has implemented measures to address the decline in operating income and improve overall profitability[4] - The company plans to enhance the review process for periodic report preparation to improve the quality of information disclosure[7] Information Disclosure - The company has committed to ensuring accurate and transparent information disclosure in its financial reporting[1] - The company reported a total related party transaction amount of 1,142.4 million yuan, with a market price of 88.12 yuan per unit[5] - The company confirmed that the total amount of expected daily related party transactions for the reporting period is 114.25 million yuan[6] - There were no significant sales returns reported during the period[6] - The company acknowledged a data entry error due to staff negligence and expressed apologies to investors[7]

江苏四环生物股份有限公司 2018 年第一季度报告正文 证券代码：000518 证券简称：四环生物 公告编号：临-2018-17 号 江苏四环生物股份有限公司 2018 年第一季度报告正文 1 江苏四环生物股份有限公司 2018 年第一季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人孙国建、主管会计工作负责人及会计机构负责人(会计主管人员) 徐海珍声明：保证季度报告中财务报表的真实、准确、完整。 2 江苏四环生物股份有限公司 2018 年第一季度报告正文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | | --- | --- | --- | --- | --- | | 营业收入（元） | 86,036,603.08 | 107,067,159.81 | | -19.64% | | 归属于上市公 ...